Atea Pharmaceuticals Inc. provided an update on its focused antiviral pipeline at the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted progress with its fixed-dose combination of bemnifosbuvir (BEM) and ruzasvir (RZR) for hepatitis C virus (HCV), noting completion of enrollment for the Phase 3 C-BEYOND trial in the US and Canada, with results expected in mid-2026. Full patient enrollment for the Phase 3 C-FORWARD trial outside North America is also anticipated by mid-2026, with results expected by year-end 2026. Atea reported cash and investments of $301.8 million as of December 31, 2025, and anticipates a cash runway through 2027. The company also announced plans to initiate a Phase 1 trial of its nucleotide prodrug AT-587 for hepatitis E virus (HEV) in mid-2026. Market insights from healthcare professionals underscore the need for shorter, easier-to-use HCV regimens to support rapid test-and-treat models. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief on January 15, 2026, and is solely responsible for the information contained therein.